(Q43758826)

26 November 2017

Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma (English)

1 reference

26 November 2017

1 reference

M Saito

1

1 reference

26 November 2017

R Takano

series ordinal

2

1 reference

26 November 2017

S Shirato

series ordinal

3

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

American Journal of Ophthalmology

26 November 2017

1 reference

26 November 2017

132

1 reference

26 November 2017

4

1 reference

26 November 2017

485-489

1 reference

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901096-0

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901096-0

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901096-0

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901096-0

Prognostic factors for hypotensive effects of isopropyl unoprostone in eyes with primary open-angle glaucoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901096-0

A comparison of the intraocular pressure-lowering effect of 0.5% timolol maleate and the docosanoid derivative of a PGF2 alpha metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901096-0

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901096-0

Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901096-0

Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901096-0

A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2801%2901096-0

10.1016/S0002-9394(01)01096-0

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference